Loading...
Docoh

PDS Biotechnology (PDSB)

Utility
Stimulation of an Immune Response by Cationic Lipids
3 Feb 22
The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
Weihsu Chen, Weili Yan, Kenya Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
Filed: 22 Jul 21
Utility
Vaccine Compositions and Methods of Use
25 Nov 21
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid.
Frank Bedu-Addo, Eric Jacobson, Kenya Johnson
Filed: 22 Jul 21
Utility
Stimulation of an Immune Response by Cationic Lipids
11 Nov 21
The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antiigens.
Weihsu Chen, Weili Yan, Kenya Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
Filed: 22 Jul 21
Utility
Cationic Lipid Vaccine Compositions and Methods of Use
11 Nov 21
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor.
Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
Filed: 22 Jul 21
Utility
Stimulation of an Immune Response by Enantiomers of Cationic Lipids
7 Oct 21
A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid.
Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
Filed: 25 Mar 21
Utility
Cationic Lipid Vaccine Compositions and Methods of Use
8 Apr 21
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor.
Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
Filed: 1 Oct 20
Utility
Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions
9 Nov 20
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor.
Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
Filed: 27 Mar 19
Utility
Stimulation of an Immune Response by Enantiomers of Cationic Lipids
21 Oct 20
A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid.
Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
Filed: 11 Jun 20
Utility
Stimulation of an immune response by enantiomers of cationic lipids
6 Jul 20
A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid.
Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
Filed: 11 Sep 17
Utility
Cationic Lipid Vaccine Compositions and Methods of Use
11 Dec 19
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor.
Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
Filed: 27 Mar 19
Utility
Improved Vaccine Compositions and Methods of Use
27 Nov 19
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid.
Frank Bedu-Addo, Eric Jacobson, Kenya Johnson
Filed: 17 Apr 19
Utility
Lipids As Synthetic Vectors to Enhance Antigen Processing and Presentation Ex-vivo In Dendritic Cell Therapy
27 Nov 19
The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies.
Frank Bedu-Addo, Greg Conn, Siva K. Gandhapudi, Martin Ward, Jerold Woodward
Filed: 5 Aug 19
  • 1
Patents are sorted by USPTO publication date, most recent first